News Humanigen facing bankruptcy as reverse merger fails Three years ago, Humanigen was riding high with a COVID-19 therapy in late-stage testing and shares worth upwards of $20 apiece.
News Eyeing emergency use of COVID-19 drug, Humanigen partners wi... Humanigen is hoping for emergency use authorisation in the US for an antibody to treat severe COVID-19 before the end of 2020, and has teamed up with Swiss contract manufacturer Lonza to ma
News Ultragenyx wins FDA approval for first treatment targeting r... Ultragenyx secured its first gene therapy approval, the FDA clearing GENGLYCOS as the first treatment designed to address underlying cause of GSDla.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
